MONDAY DEADLINE: NRx Pharmaceuticals, Inc. Investors with Significant Losses Hav… – Press Release

[ad_1]

SAN DIEGO, March 17, 2022 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. NRXP NRXPW))) securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”) have until this upcoming Monday, March 21, 2022 to seek appointment as lead plaintiff in Dal Bosco v. NRx Pharmaceuticals, Inc., No. 22-cv-00066 (D. Del.).  Commenced in the District of Delaware on January 18, 2022, the NRx Pharma class action lawsuit charges NRx as well as certain of its top executives with violations of the Securities Exchange Act of 1934. 

http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)” alt=”Robbins Geller, with 200 lawyers in ten offices, represents U.S. and international institutional investors in contingency-based securities and corporate litigation. The firm has obtained many of the largest securities class action recoveries in history, including the largest securities class action judgment. Please visit http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)”>

If you suffered significant losses and wish to serve as lead plaintiff of the NRx Pharma class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the NRx Pharma class action lawsuit must be filed with the court no later than this upcoming Monday, March 21, 2022.

CASE ALLEGATIONS: NRx is a clinical-stage small molecule pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. NRx’s products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure. In June 2021,…

[ad_2]